Positioning

Infectious Enteritis Treatment Market Size to Grow by USD 403.92 million | Increasing Geriatric Population to Drive Growth | Technavio – PR Newswire

future-dyanmics

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Jun 03, 2022, 07:15 ET
Share this article
NEW YORK, June 3, 2022 /PRNewswire/ — The infectious enteritis treatment market will be driven by factors such as the increasing geriatric population in countries such as Japan, Italy, and the US. For instance, as per the United Nations (UN) Department of Economic and Social Affairs, the geriatric population (people aged 65 or over) was 702.9 million in 2019 and 727 million in 2020. Similarly, the geriatric population in India will increase by 41% over the next decade to reach 194 million in 2031. This increase in the percentage of the geriatric population is increasing the demand for the treatment of hospital-acquired infections around the world.
The infectious enteritis treatment market size is expected to grow by USD 403.92 million from 2021 to 2026. Moreover, the growth of the market will accelerate at a CAGR of 5.09% during the forecast period. 
Request Latest Sample Report to learn about additional highlights related to market dynamics
The infectious enteritis treatment market report covers the following areas:
Subscribe to our "Basic Plan" billed annually at USD 5000. Get lifetime access to our Technavio Insights
The infectious enteritis treatment market is fragmented, and the vendors are deploying growth strategies such as geographical expansion, product portfolio expansion, and product innovation to compete in the market. The market has intense competition due to the presence of several global, regional, and local vendors. Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. are among some of the major market participants.
To learn more about major key vendors and vendor offerings, View an Exclusive Sample Report
Herpes Zoster Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026
Nicotine Patch Market by Product and Geography – Forecast and Analysis 2022-2026
Infectious Enteritis Treatment Market Scope
Report Coverage
Details
Page number
120
Base year
2021
Forecast period
2022-2026
Growth momentum & CAGR
Accelerate at a CAGR of 5.09%
Market growth 2022-2026
USD 403.92 million
Market structure
Fragmented
YoY growth (%)
3.52
Regional analysis
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 37%
Key consumer countries
US, Canada, Germany, UK, and China
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc.
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period,
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
1 Executive Summary
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source

future-dyanmics

Related posts
Positioning

Playoff positioning at stake as rivals Valwood and Brookwood clash - Valdosta Daily Times

Sunny to partly cloudy. High near 80F. Winds SW at 5 to 10 mph..
Read more
Positioning

Brand Positioning vs Unique Value Propositioning: How do they differ? [Infographic] - Media Update

media update comlies fully with the POPI act. We have taken necessary steps to secure our comuting…
Read more
Positioning

USCG Issues Safety Alert on Dynamic Positioning Systems: Don't Overestimate Their Capabilities - HS Today - HSToday

During the recent incident, a DP3 drillship suffered a complete blackout and subsequent loss of…
Read more
Newsletter
Join THE PRO PEOPLE Family

Sign up for The Pro People Community's Daily Digest and get the best of Industry updates, tailored for you.

Leave a Reply

Your email address will not be published. Required fields are marked *